Vanguard Group Inc Provention Bio, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $239,163 - $864,200	35,696 Added 0.86%	4,178,440 $101 Million
Q4 2022 Feb 10, 2023	BUY	$4.52 - $10.57 $2.43 Million - $5.69 Million	538,679 Added 14.95%	4,142,744 $43.8 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $3.52 Million - $5.77 Million	1,027,113 Added 39.86%	3,604,065 $16.2 Million
Q2 2022 Aug 12, 2022	BUY	$3.65 - $7.3 $91,757 - $183,514	25,139 Added 0.99%	2,576,952 $10.3 Million
Q1 2022 May 13, 2022	BUY	$3.4 - $7.88 $186,932 - $433,242	54,980 Added 2.2%	2,551,813 $18.7 Million
Q4 2021 Feb 14, 2022	SELL	$5.59 - $7.39 $910,689 - $1.2 Million	-162,914 Reduced 6.13%	2,496,833 $14 Million
Q3 2021 Nov 12, 2021	BUY	$5.66 - $8.33 $98,280 - $144,642	17,364 Added 0.66%	2,659,747 $17 Million
Q2 2021 Aug 13, 2021	BUY	$6.71 - $11.04 $17.7 Million - $29.2 Million	2,642,383 New	2,642,383 $22.3 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.